Reduction of Nitric Oxide with L–/Vc–Monomethyl Arginine in lnterleukin–2 and Anti–CD3 Monoclonal Antibody Combination Therapy
作者:
Fumio Nakajima,
Tomohiko Asano,
Masamichi Hayakawa,
Hiroshi Nakamura,
期刊:
International Journal of Urology
(WILEY Available online 1996)
卷期:
Volume 3,
issue 1
页码: 19-21
ISSN:0919-8172
年代: 1996
DOI:10.1111/j.1442-2042.1996.tb00075.x
出版商: Blackwell Publishing Ltd
关键词: nitric oxide;cytokine therapy;antitumor therapy
数据来源: WILEY
摘要:
We evaluated nitric oxide induction in antitumor therapy consisting of anti–CD3 monoclonal antibody (anti–CD3) and interleukin–2 (IL–2), then determined the effect of nitric oxide reduction with L–NG–monomethyl arginine (LNMA) on the therapeutic methods. Female C57BL/6 mice, MCA102 (a non immunogenic, NK–resistant murine fibrosarcoma cell line), and 145–2C11 (hamster anti–murine–CD3 mAb) were utilized in an experimental hepatic metastasis model developed by injecting a tumor cell suspension into the spleen of mice. A marked increase in serum NO2–+ NO1was observed at 19 hours after anti–CD3 (10 μ, IV) and additional IL–2 administrations (40times101U, twice, If) induced a further increase. The NO2, + NO3‐elevation in spot urine in the combination therapy was not suppressed with LNMA at a dose of 100 μg/h but was significantly lowered at 300 μg/h. The efficacy of the anti–CD3 + IL–2 therapy was not diminished by LNMA administration
点击下载:
PDF
(235KB)
返 回